Invomit

Ondansetron HCl dihydrate

Management of nausea & vomiting induced by cytotoxic chemotherapy & radiotherapy. Prevention & treatment of post-op nausea & vomiting.

Adult Highly emetogenic chemotherapy Initially 8 mg slow IV or 15 min infusion immediately before chemotherapy, followed by 1 mg/hr for up to 24 hr or a further 2 doses of 8 mg by slow IV or 15 min infusion 4 hr apart. Either regimen is then followed by 8 mg orally every 12 hr for 5 days. Less emetogenic chemotherapy 8 mg by slow IV or 15 min infusion immediately after chemotherapy or 8 mg orally 1-2 hr before chemotherapy, followed by 8 mg orally every 12 hr for 5 days. Radiotherapy-induced nausea & vomiting 8 mg orally 12 hrly 1-2 hrs before radiotherapy. Childn 5 mg/m² IV for 15 min, immediately before chemotherapy followed by 4 mg orally 12 hrly for 5 days. Hepatic impairment Not to exceed 8 mg.

May be taken with or without food.

Pregnancy & lactation.

Constipation, headache, sedation, warm sensation in the head & epigastrum; occasional transient, asymptomatic increases in aminotransferases. Rarely, hypersensitivity reactions.

Antiemetics / Supportive Care Therapy

A04AA01 - ondansetron ; Belongs to the class of serotonin (5HT3) antagonists. Used for the prevention of nausea and vomiting.

G